Ph.D., Executive Director, Kaiser Permanente Research Bank, Kaiser Permanente
Nazneen Aziz is the Executive Director of the Kaiser Permanente Research Bank (KPRB). In this role, Dr. Aziz will be responsible for strategic direction and operations of KPRB. her previous roles, Dr. Aziz was the SVP and Chief Research Officer at Phoenix Children’s Hospital, Director of Molecular Medicine at the College of American Pathologists (CAP). During her tenure at CAP, she led the development of the first set of standards and proficiency tests for clinical laboratories using next-generation sequencing. Dr. Aziz held executive leadership positions in the biotech/biopharma industry where she focused on personalized medicine, genetic tests, and development of drugs for cancer and diabetes. In her academic career, Dr. Aziz was an Assistant Professor at Harvard Medical School and Boston Children’s Hospital. Dr. Aziz received her Ph.D (molecular genetics) and MS (biochemistry) at MIT. Her publications have been cited extensively in the medical and scientific literature and she has been invited to speak at numerous national and international conferences.
Biobanks – Moving Precision Medicine Forward
Biobanks play a crucial role as they maintain a wide array of biospecimens and help move the field of precision medicine forward. As biobanks are changing the face of medical research, more biobanks are developed and maintained. This session looks at several different biobanks, their approaches of creating the research resource, how they interpret the data, and how they address results returning to both patients and physicians in a meaningful way.
Session Abstract – PMWC 2018 Silicon Valley
Session Synopsis: There has never been a better time to invest in large scale sequencing initiatives in human genetics research as the field is ripe with tremendous potential and is poised to fuel the next wave of scientific and medical advances. Technology development has enabled unprecedented scale of sequence data generation and the ability to link genomic data to high quality clinical data. This panel will touch upon recent advances and what outcomes are expected due to the revolutionary advancements of large scale sequencing and through genetics initiatives.